Defibrillatorweste

ZusammenfassungDie Defibrillatorweste („wearable cardioverter-defibrillator“, WCD) ist sicher und effektiv in der Prävention des plötzlichen Herztods und hat inzwischen Einzug in internationale Leitlinien und den klinischen Alltag gehalten. Mittlerweise sind nahezu 40.000 Patienten mit WCD-Versorgung innerhalb von klinischen Registerstudien publiziert; inzwischen wurde auch eine randomisierte Studie vorgestellt. Gerade Patienten in der Frühphase einer Kardiomyopathie mit reduzierter linksventrikulärer Funktion zeigen ein erhöhtes Risiko für ventrikuläre Tachyarrhythmien und können von einem WCD profitieren. Gerade bei diesen Patienten ohne etablierte ICD-Indikation bietet der WCD in der Phase der Etablierung und Optimierung der Herzinsuffizienzmedikation einen Schutz vor dem plötzlichen Herztod. Entscheidend für den Erfolg der WCD-Versorgung sind eine gewissenhafte Patientenselektion und ein strukturiertes Patientenmanagement. Dieser Beitrag liefert einen Überblick über die aktuelle Datenlage und Empfehlungen zum WCD.AbstractThe wearable cardioverter/defibrillator (WCD) is safe and effective in the prevention of sudden cardiac death, and has found its way into international guidelines and clinical practice. Nearly 40,000 patients with a WCD have been published in clinical registries and one randomized study has recently been presented. Especially patients with newly diagnosed cardiomyopathy with severely reduced left ventricular function show an increased risk for ventricular tachyarrhythmias and may benefit from a WCD. In these patients without an indication for an implantable cardioverter–defibrillator (ICD), the WCD offers protection from sudden cardiac death during initiation and optimization of heart failure medication. Critical patient selection and structured patient management is crucial for successful WCD prescription. This review gives an overview of the current data and recommendations on WCD.

• Publication year

  2018

• Venue

  Herzschrittmachertherapie & Elektrophysiologie

• Publication date

  2018-10-24

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00399-018-0601-zPMID 30357452
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Wearable Cardioverter–Defibrillators following Cardiac Surgery—A Single-Center Experience

  2018cited by this paper
• Outcome of Patients With In-Hospital Ventricular Tachycardia and Ventricular Fibrillation Arrest While Using a Wearable Cardioverter Defibrillator.

  2018cited by this paper
• Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator

  2018cited by this paper
• Use of the wearable cardioverter-defibrillator (WCD) and WCD-based remote rhythm monitoring in a real-life patient cohort

  2018cited by this paper
• Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.

  2018cited by this paper
• Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death

  2018cited by this paper
• Wearable cardioverter defibrillators for patients with long QT syndrome.

  2018cited by this paper
• Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting

  2018cited by this paper
• Wearable Cardioverter–Defibrillator after Myocardial Infarction

  2018cited by this paper
• The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients

  2018cited by this paper
• Experience With Wearable Cardioverter-Defibrillators at 2 Academic Medical Centers.

  2017cited by this paper
• Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis

  2017cited by this paper
• Ventricular Arrhythmia Occurrence and Compliance in Patients Treated With the Wearable Cardioverter Defibrillator Following Percutaneous Coronary Intervention.

  2017cited by this paper
• The wearable cardioverter defibrillator as a bridge to reimplantation in patients with ICD or CRT-D-related infections

  2017cited by this paper
• Real world utilization and impact of the wearable cardioverter-defibrillator in a community setting

  2017cited by this paper
• Outpatient treatment with the wearable cardioverter defibrillator: clinical experience in two Dutch centres

  2017cited by this paper
• Study of the wearable cardioverter defibrillator in advanced heart‐failure patients (SWIFT)

  2017cited by this paper
• The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients

  2017cited by this paper
• A real world wearable cardioverter defibrillator experience - Very high appropriate shock rate in ischemic cardiomyopathy patients at a European single-center.

  2017cited by this paper
• Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study

  2017cited by this paper
• Potential roles of the wearable cardioverter-defibrillator in acute phase care of patients at high risk of sudden cardiac death: A single-center Japanese experience.

  2017cited by this paper
• Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.

  2017cited by this paper
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2016cited by this paper
• Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy

  2016cited by this paper
• National experience with long-term use of the wearable cardioverter defibrillator in patients with cardiomyopathy

  2016cited by this paper
• Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death

  2016cited by this paper
• Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study.

  2016cited by this paper
• The Wearable Cardioverter Defibrillator: an Early Single Centre Australian Experience. Some Pitfalls and Caveats for Use.

  2016cited by this paper
• The Wearable Cardioverter/Defibrillator - Toy Or Tool?

  2016cited by this paper
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2016cited by this paper
• The Wearable Cardioverter Defibrillator in Nonischemic Cardiomyopathy: A US National Database Analysis.

  2016cited by this paper
• 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.

  2016cited by this paper
• Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis.

  2015cited by this paper
• Utility of the Wearable Cardioverter-Defibrillator in Patients With Newly Diagnosed Cardiomyopathy: A Decade-Long Single-Center Experience.

  2015cited by this paper
• Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation.

  2015cited by this paper
• Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients: Data From the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry)

  2015cited by this paper
• Usefulness of the wearable cardioverter defibrillator in patients in the early post‐myocardial infarction phase with high risk of sudden cardiac death: A single‐center European experience

  2015cited by this paper
• Put Into Perspective for the Practicing Clinician 735 Evolution of Left Ventricular Ejection Fraction After Acute Myocardial Infarction : Implications for Implantable Cardioverter-Defibrillator Eligibility

  2014cited by this paper
• Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function—value of the wearable cardioverter/defibrillator

  2014cited by this paper
• Use of external defibrillator jacket to facilitate safe delivery of radiotherapy for lung cancer – A report of two cases

  2014cited by this paper
• Protection from Outpatient Sudden Cardiac Death following ICD Removal Using a Wearable Cardioverter Defibrillator

  2014cited by this paper
• Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction.

  2013cited by this paper
• Early Risk of Mortality After Coronary Artery Revascularization in Patients With Left Ventricular Dysfunction and Potential Role of the Wearable Cardioverter Defibrillator

  2013cited by this paper
• Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator.

  2012cited by this paper
• Implantable cardiac defibrillators and sudden death in recent onset nonischemic cardiomyopathy: results from IMAC2.

  2012cited by this paper
• Wearable defibrillator in congenital structural heart disease and inherited arrhythmias.

  2011cited by this paper
• Bridging a Temporary High Risk of Sudden Arrhythmic Death. Experience with the Wearable Cardioverter Defibrillator (WCD)

  2010cited by this paper
• Evaluation of the effectiveness of a wearable cardioverter defibrillator detection algorithm.

  2010cited by this paper
• Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival.

  2010cited by this paper
• Defibrillator implantation early after myocardial infarction.

  2009cited by this paper
• Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction

  2005cited by this paper
• Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.

  2005cited by this paper
• Use of a Wearable Defibrillator in Terminating Tachyarrhythmias in Patients at High Risk for Sudden Death:

  2004cited by this paper
• Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.

  2004cited by this paper

• Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology—A PROLONG-II Substudy

  2022cites this paper